Marielle E. Yohe, MD, PhD, physician-scientist early investigator, Pediatric Oncology Branch, head, Molecular Signaling Section, Center for Cancer Research, National Cancer Institute, discusses the potential utility of targeting 

 mutations have been a cornerstone of targeted therapy research in many adult malignancies, such as pancreatic cancer, lung cancer, and colorectal cancer, says Yohe. However, the clinical significance of 

 mutations is largely unexplored in pediatric cancers, Yohe explains. Moreover, 

 mutations have been commonly identified in pediatric patients with 

 fusion–negative rhabdomyosarcoma, Yohe adds. 

As such, the potential clinical utility of targeting 

 mutations should not be undervalued in pediatric patients, particularly because many of the common RAS isoforms observed in this patient subgroup are not commonly identified in adult patients, Yohe says. Additionally, 

 mutations tend to occur in embryonal tumors, or tumors marked by a failure in normal development, in pediatric patients, which makes them a promising area of research, concludes Yohe.

Videos

Marielle E. Yohe, MD, PhD, discusses the potential utility of targeting RAS mutations in pediatric cancers.  



Marielle E. Yohe, MD, PhD

Articles

Dr. Yohe on the Potential to Target RAS Mutations in Pediatric Cancers